US Bancorp DE Has $396,000 Holdings in Eagle Pharmaceuticals Inc (NASDAQ:EGRX)
US Bancorp DE raised its stake in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 7.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,842 shares of the specialty pharmaceutical company’s stock after acquiring an additional 543 shares during the period. US Bancorp DE’s holdings in Eagle Pharmaceuticals were worth $396,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Park West Asset Management LLC raised its holdings in shares of Eagle Pharmaceuticals by 41.6% during the 4th quarter. Park West Asset Management LLC now owns 1,050,000 shares of the specialty pharmaceutical company’s stock worth $42,304,000 after buying an additional 308,574 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Eagle Pharmaceuticals by 121.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 285,318 shares of the specialty pharmaceutical company’s stock worth $11,495,000 after buying an additional 156,499 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Eagle Pharmaceuticals by 2,385.0% during the 4th quarter. Millennium Management LLC now owns 284,753 shares of the specialty pharmaceutical company’s stock worth $11,473,000 after buying an additional 273,294 shares in the last quarter. Norges Bank acquired a new position in shares of Eagle Pharmaceuticals during the 4th quarter worth $10,948,000. Finally, LSV Asset Management raised its holdings in shares of Eagle Pharmaceuticals by 200.2% during the 1st quarter. LSV Asset Management now owns 250,004 shares of the specialty pharmaceutical company’s stock worth $12,622,000 after buying an additional 166,715 shares in the last quarter. 94.96% of the stock is owned by hedge funds and other institutional investors.
In other Eagle Pharmaceuticals news, CEO Scott Tarriff sold 24,975 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $50.15, for a total value of $1,252,496.25. Following the sale, the chief executive officer now owns 1,500,202 shares in the company, valued at approximately $75,235,130.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Douglas L. Braunstein sold 159,223 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $56.81, for a total value of $9,045,458.63. The disclosure for this sale can be found here. Insiders own 28.20% of the company’s stock.
EGRX stock traded down $0.03 during midday trading on Friday, reaching $51.65. 3,138 shares of the stock were exchanged, compared to its average volume of 165,869. The firm has a market capitalization of $710.82 million, a P/E ratio of 24.69 and a beta of 1.58. Eagle Pharmaceuticals Inc has a 52 week low of $36.03 and a 52 week high of $85.66. The company has a quick ratio of 3.89, a current ratio of 4.12 and a debt-to-equity ratio of 0.21.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.28. The business had revenue of $49.80 million for the quarter, compared to analyst estimates of $47.03 million. Eagle Pharmaceuticals had a return on equity of 21.38% and a net margin of 17.67%. Eagle Pharmaceuticals’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 EPS. As a group, equities research analysts expect that Eagle Pharmaceuticals Inc will post 1.75 EPS for the current fiscal year.
Eagle Pharmaceuticals Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Featured Article: Do stock splits help investors?
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.